Aims: Residual beta-cell secretion in type 1 diabetes is commonly assessed by area-under-curve of plasma C-peptide concentration (AUC Cpep ) following mixed-meal tolerance test (MMTT). We aimed to investigate alternative measures of beta-cell responsiveness. 
| INTRODUCTION
The area-under-curve of sequential C-peptide concentrations (AUC Cpep ) during the mixed-meal tolerance test (MMTT) is the goldstandard method to assess residual beta-cell (ie, insulin) secretion in type 1 diabetes. 1 Traditionally, glucose excursions during the MMTT are not taken into account, although these impact on the magnitude of C-peptide response. 2 In this work, we re-analyzed MMTT data obtained in newly diagnosed children and adolescents with type 1 diabetes aged 7 to 2 (a) to identify surrogate mechanistic and pragmatic markers of AUC Cpep and (b) to explore the relationships among demographic and clinical factors, and AUC Cpep and its surrogate markers.
| METHODS
We analyzed data obtained from 32 participants with newly diag- All participants (aged ≥16 years) gave informed consent, and children <16 years gave assent and their parents gave informed consent to the study procedures.
The MMTT was performed following an overnight fast, with no food or drink other than water from midnight, and at baseline glucose levels between 4 and 11.1 mmol/L. Long-acting insulin and basal rates for insulin pump users were continued as normal. The use of rapid- (R S = 0.66 and 0.44, respectively, P < 0.01 and P < 0.05, respectively).
The total daily dose of insulin was inversely correlated with M 0 (R S = −0.42, P < 0.05) and baseline C-peptide over baseline glucose (R S = −0.38, P < 0.05). We show that M I was more tightly correlated with HbA1c than AUC Cpep (P = 0.04) indicating that M I may be a more clinically relevant marker of C-peptide secretion than AUC Cpep . The study is limited by a relatively small sample size. Further analyses with larger datasets and longitudinal evaluations are warranted. We applied parameters of Cpeptide kinetics determined in healthy subjects. As C-peptide is eliminated primarily by the kidney and assuming comparable kidney function among healthy individuals and those with recently diagnosed type 1 diabetes, we consider this limitation to be of little significance to our findings.
Alternative C-peptide secretion models assume a more complex relationship between glucose concentration and insulin secretion compared to the model used in the present study. 9, 10 These alternative models may provide additional information about C-peptide secretory characteristics but require more frequent sampling. Our parameter M I represents the dominant relationship between plasma glucose and C-peptide secretion and is accounted for in the alternative approaches. 9, 10 In conclusion, baseline C-peptide corrected for baseline glucose may be a suitable surrogate marker of residual beta-cell in newlydiagnosed type 1 diabetes. Postprandial pancreatic responsiveness estimated through a model of C-peptide kinetics appears more relevant to glucose control than the conventional area-under-curve of plasma C-peptide concentration following MMTT.
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